Müller, Stephan
Preische, Oliver
Sohrabi, Hamid R. http://orcid.org/0000-0001-8017-8682
Gräber, Susanne
Jucker, Mathias
Dietzsch, Janko
Ringman, John M.
Martins, Ralph N.
McDade, Eric
Schofield, Peter R. http://orcid.org/0000-0003-2967-9662
Ghetti, Bernardino http://orcid.org/0000-0002-1842-8019
Rossor, Martin
Graff-Radford, Neill R.
Levin, Johannes
Galasko, Douglas
Quaid, Kimberly A.
Salloway, Stephen
Xiong, Chengjie
Benzinger, Tammie
Buckles, Virginia
Masters, Colin L.
Sperling, Reisa
Bateman, Randall J.
Morris, John C.
Laske, Christoph
Article History
Received: 13 October 2016
Accepted: 29 March 2017
First Online: 27 April 2017
Competing Interests
: S.M., O.P., H.S., S.G., M.J., B.G., E.D., M.R., N.G., J.D., J.L., V.B., K.Q., C.X., T.B., C.M., R.S., and C.L. report no disclosures or potential conflicts of interest. RB has received personal compensation for activities with Link Medicine, J.A.I., Bristol-Myers Squibb Company, Pfizer Inc., Merck, SPRI, Elan Corporation, Eisai Inc., and Medtronic, Inc., received royalty payments from Washington University, and received research support from Astra Zeneca Pharmaceuticals and Merck & Co., Inc. R.N.M. is the founder and owns stock in Alzhyme. HRS has received personal compensation for activities with Pfizer and Wyeth and is the Western Australian Site Neuropsych Lead for TOMMORROW Study by the Takeda Pharmaceuticals. J.M. reports disclosures: Neither Dr. Morris nor his family owns stock or has equity interest (outside of mutual funds or other externally directed accounts) in any pharmaceutical or biotechnology company. Dr. Morris has participated or is currently participating in clinical trials of anti-dementia drugs sponsored by the following companies: Janssen Immunotherapy, and Pfizer. Dr. Morris has served as a consultant for Lilly USA. He receives research support from Eli Lilly/Avid Radiopharmaceuticals and is funded by NIH grants # P50AG005681; P01AG003991; P01AG026276 and U19AG032438”. JMR reports research support from NIH, Biogen Idec, and Eli-Lilly during the conduct of this study which is outside of the submitted work. PRS has received speaking fees from Janssen Pharmaceuticals and philanthropic support for the DIAN study from the Wicking and Mason Trusts. D.G. has served as a consultant for Prothena Pharmaceuticals, Astra-Zeneca, Balance Pharmaceuticals and Stemedica, Inc., and participates in clinical trials sponsored by Eli Lilly, Inc, Toyama and Merck Pharmaceuticals. He is funded by NIH grant AGO5131. S.S. received research support from Functional Neuromodulation, Biogen, Merck, Genentech, Roche, Lilly, and Avid Radiopharmaceuticals. He received consultation fees from Biogen, Merck, Piramal, Lilly, Genentech, and Roche. He owns no stock options or royalties and he reports no conflict of interest with this work.